Previous 10 | Next 10 |
The study, published in Nature Medicine , demonstrates that the Guardant360 ® test helps identify patients who may benefit from treatment and can identify alterations that predict resistance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology co...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force (USPSTF) and from the US Food and Drug Administration ar...
Image source: The Motley Fool. Guardant Health Inc (NASDAQ: GH) Q3 2021 Earnings Call Nov 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Guardant Health Inc (GH) Q3 2021 Earnings Call Transcript
Guardant Health, Inc. (GH) Q3 2021 Earnings Conference Call November 04, 2021 04:30 PM ET Company Participants Carrie Mendivil - Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Part...
Guardant Health (NASDAQ:GH): Q3 GAAP EPS of -$1.06 misses by $0.12. Revenue of $94.78M (+27.1% Y/Y) beats by $2.19M. Press Release Reported 22,806 tests to clinical customers and 4,839 tests to biopharmaceutical customers in the third quarter of 2021, representing an increase of 35% and 58%, ...
Achieved record revenue of $94.8 million Growth of 35% and 58% year over year in clinical and biopharma volumes, respectively Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its propri...
Increased accessibility to Guardant Health’s liquid biopsy testing will enable clinicians to personalize treatments more accurately for patients with late-stage cancer Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and The Royal Marsden NHS Foun...
This study indicates Guardant Health’s blood test could provide meaningful clinical performance in an average risk screening population Guardant Health, Inc. (Nasdaq: GH), presents data at the American College of Gastroenterology Annual Scientific Meeting being held f...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors. “We are very pleased to welcome Myrtle Potter to our Board of Directors as we continue to build and deliver on our mission of conquering c...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Higher yields as well as uncertainty over inflation, supp...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...